Drug intelligence / Profile preview

OWL-4130-AI

Development stage: Preclinical
Lead developer: Owl Therapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

OWL-4130-AI is a preclinical-stage recombinant fusion protein developed by Owl Therapeutics for the treatment of Alzheimer's Disease (AD) and Traumatic Brain Injury (TBI). It was engineered using generative AI to function as a 'supercharged microglial' therapeutic, aimed at enhancing and protecting microglial cells—the primary immune cells of the central nervous system. By modulating microglial activity, the drug seeks to address neuroinflammation and promote brain health in neurodegenerative and traumatic contexts. As of early 2024, the candidate is in preclinical development.

Beyond the preview

Go deeper on OWL-4130-AI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OWL-4130-AI.

Explore the full profile